{
    "medicine_id": "b16d4e25c9887a8ae25e10aeca3c086ec9d09b57",
    "platform_id": "DB13173",
    "metadata": {
        "name": "Brineura 150 mg 5mL Kit",
        "composition": "150 mg 5mL Cerliponase alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Cerliponase alfa is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 CLN2 disease to decelerate the progressive motor function decline in patients 3 years of age and older CLN2 disease is a form of Batten disease a rare inherited neurodegenerative disorder and is associated with seizures ataxia rapid loss of language and motor functions blindness and early death L755 It is caused by the lack the lysosomal enzyme tripeptidyl peptidase 1 TPP1 and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system",
            "contraindications": {
                "disease": "No data from carcinogenicity genotoxicity and fertility studies Unwanted effects of cerliponase alfa treatment include pyrexia ECG abnormalities decreased CSF protein seizure and hypersensitivity",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Cerliponase alfa contains the active substance tripeptidyl peptidase 1 rhTPP1 a recombinant human lysosomal exopeptidase which cleaves the N terminal of tripeptides with a broad substrate specificity Cerliponase alfa slows the progressive decline in motor function caused by abnormal motor signalling in the brain by restoring the normal levels and activity of TPP1",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}